Boehringer Ingelheim’s survodutide shows promise in liver fibrosis treatment
Phase 2 trial reveals significant improvement in MASH patients
Read More
Tag: survodutide
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
